- Product
- Efficacy vs. More inoculation? Vaccination plan in dilemma
- by Choi-sun Jan 22, 2021 06:26am
- The public is questioning the actual efficacy of the alternative regimen of the COVID-19 vaccine that reduces dose or delays the booster dose due to the vaccine shortage, Relevant experts give conflicted opinions. Some argue the government should maximize the efficacy with the limited resource, whereas some claim medical evidence is integral
- Company
- Takeda to retry expanding all-comer coverage on Zejula
- by Eo, Yun-Ho Jan 21, 2021 06:15am
- An all-comer targeting anticancer treatment Zejula is shooting yet again for the healthcare reimbursement expansion this year. The pharmaceutical industry insider reported the drug could not overcome the hurdle of the Health Insurance Review and Assessment Service (HIRA) Cancer Deliberation Committee in last June, but the poly ADP-ribose
- Policy
- GemVax dementia drug candidate is reviewed for PSP
- by Lee, Tak-Sun Jan 21, 2021 06:14am
- It is considering clinical trials to verify the new drug candidate GV1001, which GemVax is developing as a treatment for Alzheimer's disease, for the rare disease progressive supranuclear pals. However, the Central Pharmaceutical Affairs Review Committee, an expert advisory body from the MFDS, has postponed the judgment that additional da
- Company
- Daewoong & Boryung challenged the patent for Sprycel
- by Kim, Jin-Gu Jan 21, 2021 06:13am
- Daewoong challenged the patent for BMS' chronic myelogenous leukemia treatment Sprycel (Dasatinib). As other domestic companies have failed to overcome the patents one after another, attention is focused on Daewoong's challenge. According to the pharmaceutical industry on the 19th, Daewoong recently requested an invalidation trial again
- Policy
- Paclitaxel + Carboplatin + RT will be reimbursed
- by Lee, Hye-Kyung Jan 21, 2021 06:13am
- Paclitaxel+Carboplatin+RTprior chemotherapy, which required prior approval from the Director of the HIRA, will be reimbursed for anticancer therapy The HIRA announced that it plans to announce an amendment to the announcement of drugs prescribed/administered to cancer patients containing the above contents, and that opinion inquiry will b
- Company
- “Yuhan’s change is just warming up with Leclaza”
- by An, Kyung-Jin Jan 21, 2021 06:13am
- “We believed the path for Yuhan Corporation taking the step forward to another century ahead would be through new drug pipeline. We are exhilarated to see the world acknowledging the company’s first proud outcome of the open innovation strategy, Leclaza (lazertinib).” During an interview with Daily Pharm on Jan. 18, Yuhan Corporation
- Company
- Tumor-agnostic Rozlytrek applies for NHI coverage
- by Eo, Yun-Ho Jan 20, 2021 06:04am
- A tumor-agnostic anticancer medicine Rozlytrek is shooting for the National Health Insurance (NHI) reimbursement listing. A pharmaceutical industry source reported Roche Korea submitted a reimbursement listing application for a neurotrophic tyrosine receptor kinase (NTRK) targeted therapy Rozlytrek (entrectinib) to a South Korean health
- Opinion
- [Reporter's View] Yuhan's Open Innovation Success Model
- by Kim, Jin-Gu Jan 20, 2021 06:02am
- Until only five years ago, Yuhan was the No. 1 pharmaceutical company in Korea, but it was criticized for being a company that sells foreign drugs and only acts as a wholesaler. The company had very few pipelines. However, since President Lee Jung-hee took office in 2015, Yuhan's new drug pipeline has increased to 29 as of the end of last
- Policy
- Conditional approval on Celltrion COVID-19 treatment advised
- by Lee, Tak-Sun Jan 20, 2021 06:02am
- The South Korean health authority’s panel of experts verified the clinical results and advised an approval of Celltrion’s COVID-19 monoclonal antibody treatment candidate Rekirona with a condition to conduct Phase III trial. The panel recommended the drug to be used to alleviate the mild to moderate COVID-19 symptoms in adult patients.
- Policy
- Yuhan's Lazertinib was approved
- by Lee, Tak-Sun Jan 20, 2021 06:02am
- The new drug Lazertinib developed by Yuhan for the treatment of non-small cell lung cancer has obtained approval from the MFDS. The technology was transferred to the global pharmaceutical company Janssen and is currently undergoing licensing procedures in other countries such as the United States. It is the first country in the world to obtai
